Stack Evidence
Check whether a combination has actually been studied together. Separate component evidence is not automatically evidence of synergy.
Combination evidence pages
Browse existing combination pages. Component evidence is kept separate from evidence that studied the combination itself.
BPC-157 + TB-500
A 2026 rat Achilles-tendon study directly tested the combination. It improved some histology versus control but did not add benefit over either monotherapy.
Open combination page →CagriSema in type 2 diabetes
REIMAGINE 2 enrolled 2,713 participants and found greater HbA1c reduction with CagriSema 2.4/2.4 mg versus semaglutide 2.4 mg; gastrointestinal disorders were the most common adverse events.
Open combination page →Cagrilintide + semaglutide (CagriSema)
REDEFINE 1 reported -20.4% mean weight change versus -3.0% with placebo at 68 weeks in obesity.
Open combination page →CJC-1295 + Ipamorelin
CJC-1295 and ipamorelin each have human endocrine/PK evidence, but that does not establish additive benefit, an optimal ratio or long-term safety for the combination.
Open combination page →GHK-Cu + BPC-157 + TB-500 (Glow blend)
The 2026 BPC-157 + TB-500 rat study provides partial-stack preclinical evidence only.
Open combination page →KLOW blend
KLOW is a community/market name commonly used for a KPV + GHK-Cu + BPC-157 + TB-500 blend.
Open combination page →MOTS-c + SS-31/elamipretide
Separate evidence for MOTS-c and elamipretide does not establish additive mitochondrial benefit or combination safety.
Open combination page →Retatrutide + cagrilintide
Retatrutide and cagrilintide each have separate human development programmes, but separate trial findings do not establish that combining them is more effective or safe.
Open combination page →Semax + Noopept
Separate human evidence for each compound cannot establish added cognitive benefit, compatibility or optimal dosing when combined.
Open combination page →Semax + Selank
Semax and Selank each have separate human evidence, but no robust combination-specific human trial was identified in the current search.
Open combination page →